A panel of European Medicines Agency recommended approval for Pfizer Inc.’s Zirabev, a cheaper version to Roche Holding AG’s leading cancer drug Avastin.
Shares of Johnson & Johnson tumbled 12 percent after Reuters reported that the pharma major knew for decades that cancer-causing asbestos lurked in the company’s Baby Powder.
People with inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis may be up to 12 times more likely to have a heart attack, a U.S. study suggests.
Four Democratic U.S. senators introduced a bill that would allow the government to block drug price increases that are unjustified.
Google said on Thursday the company had launched an artificial intelligence program in Thailand to screen for a diabetic eye disease that causes permanent blindness.
U.S. generics drugmaker Mylan said the United States Patent and Trademark Office rejected Sanofi’s infringement claims relating to insulin drug Lantus.
In men with localized prostate cancer discovered because they had symptoms or noticed during a work-up for another medical problem, radical prostate surgery leads to an average of three extra years of life compared to a “watchful waiting” approach, researchers say.
Johnson & Johnson said the company’s drug Tremfya was more effective than Novartis AG’s rival medicine Cosentyx, and met the main goal of a late-stage study in adults with moderate-to-severe plaque psoriasis.
The U.S. Food and Drug Administration declined to approve an abuse-deterrent version of Mallinckrodt Plc’s opioid painkiller Roxicodone, saying some parts of the company’s application need further evaluation.
U.S. drugmaker Eli Lilly and Co. and AC Immune SA agreed to jointly develop the Swiss biotech’s potential treatment for Alzheimer’s disease.